Catestatin vs Elabela — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Catestatin is a 21-amino acid peptide derived from the chromogranin A (CgA) protein, specifically cleaved from the region spanning residues 352-372. It was identified as an endogenous inhibitor of catecholamine secretion, acting as a non-competitive antagonist at nicotinic acetyl...
Calculate Catestatin dose →Elabela (also called Apela or Toddler) is the second endogenous peptide ligand for the APJ receptor, discovered in 2013 independently through two approaches: as an essential zebrafish cardiac development factor (Toddler) and as a novel human APJ ligand (Elabela). Unlike apelin pe...
Calculate Elabela dose →| Parameter | Catestatin | Elabela |
|---|---|---|
| Category | Cardiovascular Peptide | Cardiovascular Peptide |
| Research | Preclinical / Early Human | Research |
| Half-Life | ~15-30 minutes (IV) | Short (minutes, estimated) |
| Typical Dose | 0.3-3 nmol/kg (animal studies) | 5-500 nmol/kg (animal) |
| Frequency | Acute dosing in research | Variable |
| Route | IV (research); intranasal under study | Subcutaneous, Intravenous |
| FDA Status | Research compound | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.